跳到正文
原文
The Lancet Respiratory Medicine· Lizza E L Hendriks, Jessica J Lin, Daniel S W Tan, Fabian Acker, Francesca R Ogliari, May-Lucie Meyer, David Planchard, Martin Reck·· 2026-09-07AI 评分30

The Lancet Respiratory Medicine 系列综述:晚期 NSCLC 靶向治疗的新生物标志物与治疗策略

[Series] Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies

AI 导读

The Lancet Respiratory Medicine 系列第二篇综述总结晚期非小细胞肺癌(NSCLC)靶向治疗进展,覆盖 EGFR、ALK、ROS1、KRAS、BRAF、RET、HER2、MET、NTRK 等已确立的驱动变异,并讨论 NRG1 融合、MTAP 缺失、SMARCA4 缺陷等新兴靶点。

来源:The Lancet Respiratory Medicine · thelancet.com